Selenium-containing triphenyl ethylene compound as well as preparation method and application thereof

By developing selenium-containing triphenylethylene compounds, especially compound 109, the problem of tamoxifen's poor treatment effect on hormone receptor-positive and triple-negative breast cancer has been solved, and effective inhibition of a variety of breast cancer cells has been achieved. , significantly improve the therapeutic effect.

CN119059948APending Publication Date: 2024-12-03NANJING UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411174224.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing breast cancer treatment drug tamoxifen has limited efficacy in hormone receptor-positive breast cancer, especially in patients with triple-negative breast cancer (TNBC), and has high recurrence and drug resistance problems.

Method used

A class of selenium-containing triphenylethylene compounds and their preparation methods were developed, and tetrasubstituted olefin compounds were prepared through specific selenacetylene carbon borolation reactions, which had good anti-tumor activity. Specific compounds 109 were used to treat multiple breast cancer cell lines. Shows significant inhibitory effect.

Benefits of technology

Compound 109 significantly reduced the IC50 of human breast cancer cells MCF-7, SUM-159PT and 4T1. Compared with tamoxifen in vivo experiments, it significantly improved the inhibitory effect of MCF-7 and 4T1 transplant tumors, showing a stronger Anti-tumor potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119059948A_ABST
    Figure CN119059948A_ABST
Patent Text Reader

Abstract

The invention discloses preparation and application of a selenium-containing triphenyl ethylene derivative, the structure of the selenium-containing triphenyl ethylene derivative is shown as a formula I. The compound is novel in structure and simple in preparation method, tetra-substituted olefin can be specifically stereoselectively obtained by developing novel selenyne 1, 1-carbon boronation reaction, and interference of other isomers is avoided. The compound has good anti-tumor activity, and compared with tamoxifen, the inhibition of the compound 109 with equal molar concentration on the proliferation of MCF-7 xenotransplantation tumors is improved by 31.68%; the inhibition of 4T1 transplanted tumor proliferation is improved by 109.37%, which indicates that the compound 109 has great application value in the anti-tumor aspect. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of pharmaceutical chemistry, and specifically relates to a selenium-containing triphenylethylene compound and a preparation method and application thereof. Background Art

[0003] Breast cancer can be divided into three major subtypes according to whether it expresses estrogen receptor (ER) or progesterone receptor (PR) and human epidermal growth factor 2 (ERBB2, HER2) molecular markers, namely hormone receptor positive / ERBB2 negative (HR+ / ERBB2-), ERBB2 positive (HR+or HR- / ERBB2+) and triple negative breast cancer (TNBC). Currently, postoperative adjuvant endocrine therapy is the main clinical treatment for hormone receptor positive breast cancer, but due to the heterogeneity of tumors, breast cancer often shows a high recurrence rate and drug resistance. TNBC accounts for about 15% to 25% of all breast cancers, and has the characteristics of strong invasiveness, high recurrence rate, resistance to chemotherapy drugs and poor prognosis. The clinical treatment of TNBC is mainly surgery-assisted radiotherapy and chemotherapy, but about 35% of TNBC patients still have recurrence and metastasis, and the survival period is short.

[0004] Tamoxifen (TAM) is mainly used for hormone therapy in patients with hormone receptor-positive breast cancer, endometrial cancer, and ovarian cancer recurring after chemotherapy. It competitively interferes with the binding of estrogen to ER, thereby blocking the signal transduction of ERα. The failure rate of TAM in the clinical treatment of patients with advanced hormone receptor-positive breast cancer is as high as 50%, leading to tumor recurrence and metastasis; the overall effective rate in the treatment of ovarian cancer is only about 10%; for patients with low ER expression and TNBC breast cancer, the efficacy of TAM is very limited. Therefore, it is of great significance to improve the tumor suppressor activity of TAM and find safe and effective drugs for the treatment of female breast cancer. Summary of the invention

[0005] In view of the deficiencies in the prior art, the present invention provides a selenium-containing triphenylethylene compound and a preparation method and application thereof.

[0006] The technical solution of the present invention is as follows: The compound represented by formula I or its pharmaceutically acceptable salt or isomer thereof

[0007]

[0008] Wherein R1 is selected from hydrogen, halogen, hydroxyl, R a OR bO-, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, CN, NO2, formyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C6 alkylthio, substituted or unsubstituted C1-C6 alkylcarbonyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; wherein the substituted substituents are each independently selected from halogen, C1-C3 alkyl;

[0009] R2 is selected from R e R f N-, C1~C6 alkoxy, C1~C6 alkyl or halogenated C1~C6 alkyl; wherein R a , R b , R c or R d Each is independently selected from hydrogen, halogen, C1-C3 alkyl or halogenated C1-C3 alkyl;

[0010] R3 is selected from hydrogen, halogen, hydroxyl, substituted or unsubstituted C1-C6 alkoxy, CN, NO2, formyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C6 alkylthio, substituted or unsubstituted C1-C6 alkylcarbonyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; wherein the substituted substituents are each independently selected from halogen, C1-C3 alkyl;

[0011] Where R a , R b , R c , R d , R e or R f Each is independently selected from hydrogen, halogen, C1-C3 alkyl or halogenated C1-C3 alkyl.

[0012] In some embodiments, R1 is selected from hydrogen, halogen, hydroxyl, R a OR b O- or C1~C6 alkoxy.

[0013] In some typical embodiments, R1 is selected from hydrogen, chlorine, bromine, iodine, hydroxyl, methoxy or CH3OCH2O-.

[0014] In some embodiments, R2 is selected from R e R f N-or

[0015] In some typical embodiments, R2 is selected from dimethylamino, diethylamino or

[0016] In some embodiments, R3 is selected from hydrogen, C1-C6 alkoxy, or C1-C6 alkyl.

[0017] In some typical embodiments, R3 is selected from hydrogen, methoxy or isopropyl.

[0018] In some typical embodiments, the compound represented by Formula I has the structure represented by Formula I-1

[0019]

[0020] Wherein R1 is selected from hydrogen, chlorine, bromine, iodine, hydroxyl, methoxy or CH3OCH2O-;

[0021] R2 is selected from dimethylamino, diethylamino or

[0022] R3 is selected from hydrogen, methoxy or isopropyl.

[0023] The following compounds or their pharmaceutically acceptable salts or isomers,

[0024]

[0025] The present invention also provides a method for preparing the compound shown in formula I, comprising the following steps:

[0026]

[0027] Wherein R1, R2 and R3 are substituents defined in formula I, X is selected from bromine or iodine.

[0028] Step a): dissolving and mixing the compound of formula V and the compound of formula IV in a solvent, and reacting them in the presence of pinacol and a base to obtain a compound of formula III;

[0029] Step b): dissolving and mixing the compound of formula III and the compound of formula III-1 in a solvent, and reacting them in the presence of a base and a catalyst to obtain a compound of formula II;

[0030] Step c): The compound of formula II is reacted with R2H in a solvent in the presence of a base and a catalyst to prepare a compound of formula I.

[0031] Wherein, the solvent in step a) is DCE and the base is triethylamine.

[0032] The solvent in step b) is THF, the base is KOH, and the catalyst is Pd(dppf)2Cl2.

[0033] The solvent in step c) is DMF, the base is K2CO3, and the catalyst is KI.

[0034] Another object of the present invention is to provide the use of the compound of formula I in the preparation of anti-breast cancer, endometrial cancer or ovarian cancer drugs, wherein the breast cancer cells include human hormone receptor-positive breast cancer cell line MCF-7, human triple-negative breast cancer cell line SUM-159PT and triple-negative breast cancer cell line 4T1, endometrial cancer cells include human endometrial cancer cell line AN3CA, and ovarian cancer cells include human ovarian cancer cell line SK-OV-3.

[0035] The present invention provides a composition comprising a compound of formula I, which comprises a therapeutically effective amount of the compound of formula I or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

[0036] The pharmaceutically acceptable carrier refers to various conventional excipients required when preparing different dosage forms, such as diluents, binders, disintegrants, glidants, lubricants, flavoring agents, inclusion materials, adsorption materials, etc., which are prepared into any commonly used preparations using conventional preparation methods.

[0037] Beneficial effects of the invention: The invention discloses the preparation and application of a class of selenium-containing triphenylethylene derivatives. The structure of the compounds is novel, and the advantage of the synthetic route is that by developing a new type of selenyne 1,1-carboboration reaction, such tetrasubstituted olefins can be obtained stereoselectively without interference from other isomers. The compounds have good anti-tumor activity, especially compound 109 has the strongest activity. The results of in vitro experiments show that the half inhibitory concentration (IC50) of compound 109 on the human breast cancer cell line MCF-7 is 50 ) is 8.94 μM; IC for the human triple-negative breast cancer cell line SUM-159PT 50 The IC value for the mouse triple-negative breast cancer cell line 4T1 is 17.72 μM. 50 The IC value for human endometrial cancer cell line AN3CA is 11.31 μM. 50 is 12.72μM; IC 50 The IC of compound 109 against human ovarian cancer SK-OV-3 was significantly lower than that of TAM. 50 The IC50 of compound 109 was 20.05 μM, which was equivalent to the anti-tumor activity of TAM (IC50 was 21.60 μM). The results of in vivo experiments showed that compared with tamoxifen, the equimolar concentration of compound 109 inhibited the proliferation of MCF-7 xenograft tumors by 31.68% and inhibited the proliferation of 4T1 xenograft tumors by 109.37%. These effects indicate that compound 109 has great application value in anti-tumor. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 The half maximal inhibitory concentration (IC50) of compounds 109-119 on the human breast cancer cell line MCF-7 was determined.

[0039] Figure 2 The half-maximal inhibitory concentration (IC50) of compounds 109-119 on the mouse breast cancer cell line 4T1 was determined.

[0040] Figure 3 The effect of compound 109 on the tumor volume growth of breast cancer cell MCF-7 and 4T1 transplanted tumors.

[0041] Figure 4 The picture shows the effect of compound 109 on the tumor volume of breast cancer cell MCF-7 and 4T1 transplanted tumors.

[0042] Figure 5 The effect of compound 109 on tumor weight of breast cancer cell MCF-7 and 4T1 xenograft tumors.

[0043] Figure 6 The effect of compound 109 on the body weight of mice bearing breast cancer cell MCF-7 and 4T1 xenograft tumors.

[0044] Figure 7 The effect of compound 109 on the liver and kidney tissue morphology of tumor-bearing mice (H&E staining). DETAILED DESCRIPTION

[0045] The following embodiments can enable those skilled in the art to more fully understand the present invention, but the present invention is not limited to the scope of the embodiments.

[0046] Example 1: Preparation of a selenium-containing triphenylethylene derivative.

[0047] The specific preparation reaction is as follows:

[0048]

[0049] In this example, 11 selenium-containing triphenylethylene derivatives, namely compounds 109-119, were prepared.

[0050] The structures, preparation steps and spectral data of compounds 109-119 are as follows:

[0051]

[0052] Synthesis and spectral data of 109:

[0053] 1) Phenyl acetylene (5 mmol, 1 equiv.) was weighed into a 100 mL sealed tube with a magnetic stirrer. THF (10 mL) was added under nitrogen atmosphere. After it was fully dissolved at room temperature, the reaction mixture was placed in a low-temperature reaction bath at -78°C and slowly added dropwise with a syringe. nBuLi (1.2 equiv., 2.5 M in THF), the reaction was stirred at -78 ° C for 30 minutes, then Se2Me2 (1.2 equiv.) was added at -78 ° C, the reaction was moved to room temperature for 4 hours, and after the reaction was completed, saturated NH4Cl solution (5 mL) was added to quench the reaction. Extracted with EA (3x 15 mL), the organic phases were combined, dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using PE as the eluent, and the target product methyl (phenylethynyl) selenane was finally obtained with a yield of 90% as a yellow oil.

[0054] 2) Phenylboronic acid (15 mmol, 1 equiv.) was weighed into a 200 mL round-bottom flask with a magnetic stirrer, and anhydrous ethanol (15 mL) was added. After sufficient dissolution, 30% H2O2 (14 equiv.) was added while stirring. The reaction was then stirred at room temperature for 1 minute. After the reaction was completed, water (150 mL) was added to quench the reaction. EA was extracted (3 x 200 mL), and the organic phases were combined, dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The product did not need to be subjected to column chromatography, and the purity could be determined by TLC. 4-(trimethylsilyl)phenol was obtained in almost equivalent reaction as a colorless oil.

[0055] 3) 4-(Trimethylsilyl)phenol (15mmol, 1equiv.) was weighed into a 100mL round-bottom flask with a magnetic stirrer, and tetrabutylammonium bromide (0.1equiv.), NaOH (10equiv.), and DCM (12mL) were added in sequence. The reaction was stirred at room temperature for 30 minutes, and then 1-bromo-2-chloroethane (4equiv.) was added. The reaction was stirred at room temperature for 48 hours. After the reaction was completed, water (10mL) was added to quench the reaction. Extraction with DCM (3x 20mL), the organic phases were combined, the organic phases were dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using PE:EA (20:1) as the eluent, and the target product (4-(2-chloroethoxy)phenyl)trimethylsilane) was finally obtained with a yield of 78% as a colorless oil.

[0056] 4) Weigh (4-(2-chloroethoxy)phenyl)trimethylsilane (3 equiv.) in a 350 mL sealed tube with a magnetic stirrer, add DCM (15 mL) under nitrogen atmosphere, and after it is fully dissolved, add BCl3 (6 equiv., 1 M in DCM). The reaction is stirred at room temperature for 24 hours and then vacuumed for 1 hour to remove the solvent. Then, DCE (15 mL) is added under nitrogen atmosphere. After it is fully dissolved, methyl (phenylethynyl) selenane (3 mmol, 1 equiv.) is added, and the reaction is stirred at room temperature for 12 hours. Then, under nitrogen atmosphere, a mixed solution of pinacol (5 equiv.) and NEt3 (5 equiv.) is added to the reaction tube and reacted at room temperature for 1 hour. After the reaction is completed, MTBE is added to quench the reaction and the solvent is removed by rotary evaporation. The crude product was purified by column chromatography using PE:EA (10:1) as the eluent to obtain the target product (E)-2-(1-(4-(2-chloroethoxy)phenyl)-2-(methylphenylvinyl)-2-phenylvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane as a yellow solid in a yield of 78%.

[0057] 1 H NMR (500MHz, CDCl3) δ = 7.18-7.14 (m, 5H), 6.94 (d, J = 8.7Hz, 2H), 6.61 (d, J = 8.7Hz ,2H),4.11(t,J=6.0Hz,2H),3.73(t,J=6.0Hz,2H),1.76(s,3H),1.37(s,12H)ppm; 13 C NMR (126MHz, CDCl3) δ = 156.3, 141.0, 139.5, 133.8, 130.3, 130.0, 128.0, 126.9, 114.0, 84.2, 67.7, 41.9, 24.8, 6.8ppm; HRMS (ESI): Exact mass calculated for C 23 H 28 BClO3Se+H + :479.1058,mass found:479.1058.

[0058] 5) Weigh (E)-2-(1-(4-(2-chloroethoxy)phenyl)-2-(methylphenylvinyl)-2-phenylvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborane (1 mmol, 1 equiv.), Pd(dppf)2Cl2 (10 mol%) in a 25 mL sealed tube, add THF (5 mL), 1-iodo-4-(methoxymethoxy)benzene (2.1 equiv.), KOH (4 equiv. 9 M inH2O) under nitrogen atmosphere, then stir the reaction at room temperature for 1 hour, add water (3 mL) after the reaction is completed to quench the reaction. Extract with EA (3x10 mL), combine the organic phases, dry the organic phases over anhydrous Na2SO4, and remove the solvent by rotary evaporation. The obtained crude product does not need to be purified and is directly used in the next step. The crude product (1 equiv.), KI (1 equiv.), dimethylamine hydrochloride (10 equiv.), and K2CO3 (5 equiv.) were weighed into a 25 mL sealed tube with a magnetic stirrer. DMF (1 mL) was added under nitrogen atmosphere, and then the reaction tube was placed in an oil bath at 100°C and heated with stirring for 12 hours. After the reaction was completed, the temperature was cooled to room temperature and water (3 mL) was added to quench the reaction. EA was used for extraction (3 x 20 mL), and the organic phases were combined, washed with water (3 x 5 mL), dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using DCM:MeOH (50:1) as the eluent to obtain the target product 109 as a yellow oil with a yield of 67%.

[0059] 1 H NMR (500MHz, CDCl3) δ = 7.31 (d, J = 8.0Hz, 2H), 7.24–7.11 (m, 5H), 7.04 (d, J = 8.0Hz, 2H), 6.82 (d, J = 8.0Hz, 2H), 6.55 (d ,J=8.0Hz,2H),5.20(s,2H),4.02(t,J=5.0Hz,2H),3.50(s,3H),2.83(t,J=5.0Hz,2H),2.42(s,6H),1.62(s,3H)ppm; 13 C NMR (126MHz, CDCl3) δ = 156.5, 156.3, 140.3, 139.9, 137.7, 135.4, 132.4, 131.3, 130.9, 13 0.5,128.1,126.7,115.9,113.5,94.5,64.8,57.9,56.1,45.4,7.1ppm; HRMS(ESI):Exact masscalculated for C 27 H 31 NO3Se+H +:498.1542,mass found:498.1537.

[0060]

[0061] Synthesis and Spectrum Data of 110:

[0062] 1) Phenyl acetylene (5 mmol, 1 equiv.) was weighed into a 100 mL sealed tube with a magnetic stirrer. THF (10 mL) was added under nitrogen atmosphere. After it was fully dissolved at room temperature, the reaction mixture was placed in a low-temperature reaction bath at -78°C and slowly added dropwise with a syringe. n BuLi (1.2 equiv., 2.5 M in THF), the reaction was stirred at -78 ° C for 30 minutes, then Se2Me2 (1.2 equiv.) was added at -78 ° C, the reaction was moved to room temperature for 4 hours, and after the reaction was completed, saturated NH4Cl solution (5 mL) was added to quench the reaction. Extracted with EA (3x 15 mL), the organic phases were combined, dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using PE as the eluent, and the target product methyl (phenylethynyl) selenane was finally obtained with a yield of 90% as a yellow oil.

[0063] 2) Phenylboronic acid (15 mmol, 1 equiv.) was weighed into a 200 mL round-bottom flask with a magnetic stirrer, and anhydrous ethanol (15 mL) was added. After sufficient dissolution, 30% H2O2 (14 equiv.) was added while stirring. The reaction was then stirred at room temperature for 1 minute. After the reaction was completed, water (150 mL) was added to quench the reaction. EA was extracted (3 x 200 mL), and the organic phases were combined, dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The product did not need to be subjected to column chromatography, and the purity could be determined by TLC. 4-(trimethylsilyl)phenol was obtained in almost equivalent reaction as a colorless oil.

[0064] 3) 4-(Trimethylsilyl)phenol (15mmol, 1equiv.) was weighed into a 100mL round-bottom flask with a magnetic stirrer, and tetrabutylammonium bromide (0.1equiv.), NaOH (10equiv.), and DCM (12mL) were added in sequence. The reaction was stirred at room temperature for 30 minutes, and then 1-bromo-2-chloroethane (4equiv.) was added. The reaction was stirred at room temperature for 48 hours. After the reaction was completed, water (10mL) was added to quench the reaction. Extraction with DCM (3x 20mL), the organic phases were combined, the organic phases were dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using PE:EA (20:1) as the eluent, and the target product (4-(2-chloroethoxy)phenyl)trimethylsilane) was finally obtained with a yield of 78% as a colorless oil.

[0065] 4) Weigh (4-(2-chloroethoxy)phenyl)trimethylsilane (3 equiv.) in a 350 mL sealed tube with a magnetic stirrer, add DCM (15 mL) under nitrogen atmosphere, and after it is fully dissolved, add BCl3 (6 equiv., 1 M in DCM). The reaction is stirred at room temperature for 24 hours and then vacuumed for 1 hour to remove the solvent. Then, DCE (15 mL) is added under nitrogen atmosphere. After it is fully dissolved, methyl (phenylethynyl) selenane (3 mmol, 1 equiv.) is added, and the reaction is stirred at room temperature for 12 hours. Then, under nitrogen atmosphere, a mixed solution of pinacol (5 equiv.) and NEt3 (5 equiv.) is added to the reaction tube and reacted at room temperature for 1 hour. After the reaction is completed, MTBE is added to quench the reaction and the solvent is removed by rotary evaporation. The crude product was purified by column chromatography using PE:EA (10:1) as the eluent to obtain the target product (E)-2-(1-(4-(2-chloroethoxy)phenyl)-2-(methylphenylvinyl)-2-phenylvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane as a yellow solid in a yield of 78%.

[0066] 1 H NMR (500MHz, CDCl3) δ = 7.18-7.14 (m, 5H), 6.94 (d, J = 8.7Hz, 2H), 6.61 (d, J = 8.7Hz ,2H),4.11(t,J=6.0Hz,2H),3.73(t,J=6.0Hz,2H),1.76(s,3H),1.37(s,12H)ppm; 13 CNMR (126MHz, CDCl3) δ = 156.3, 141.0, 139.5, 133.8, 130.3, 130.0, 128.0, 126.9, 114.0, 84.2, 67.7, 41.9, 24.8, 6.8ppm; HRMS (ESI): Exact mass calculated for C 23 H 28 BClO3Se+H + :479.1058,mass found:479.1058.

[0067] 5) Weigh (E)-2-(1-(4-(2-chloroethoxy)phenyl)-2-(methylphenylvinyl)-2-phenylvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborane (1 mmol, 1 equiv.), Pd(dppf)2Cl2 (10 mol%) in a 25 mL sealed tube, add THF (5 mL), p-bromoiodobenzene (2.1 equiv.), KOH (4 equiv.9 M in H2O) under nitrogen atmosphere, then stir the reaction at room temperature for 1 hour, add water (3 mL) after the reaction is completed to quench the reaction. Extract with EA (3 x 10 mL), combine the organic phases, dry the organic phases over anhydrous Na2SO4, and remove the solvent by rotary evaporation. The crude product is directly used for the next step without purification. The crude product (1 equiv.), KI (1 equiv.), dimethylamine hydrochloride (10 equiv.), and K2CO3 (5 equiv.) were weighed into a 25 mL sealed tube with a magnetic stirrer. DMF (1 mL) was added under nitrogen atmosphere, and then the reaction tube was placed in an oil bath at 100°C and heated with stirring for 12 hours. After the reaction was completed, the temperature was cooled to room temperature and water (3 mL) was added to quench the reaction. EA was used for extraction (3 x 20 mL), and the organic phases were combined, washed with water (3 x 5 mL), dried with anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using DCM:MeOH (50:1) as the eluent, and the target product 110 was finally obtained with a yield of 65% as a yellow solid with a melting point of 112.6-113.3°C.

[0068] 1 H NMR (500MHz, CDCl3) δ = 7.50 (d, J = 8.0Hz, 2H), 7.31–7.12 (m, 7H), 6.78 (d, J = 8.0Hz, 2H), 6.55 (d, J = 8.0 Hz,2H),3.91(t,J=5.0Hz,2H),2.63(t,J=5.0Hz,2H),2.28(d,J=4.5Hz,6H),1.64(d,J=4.5Hz,3H)ppm; 13 C NMR(126MHz, CDCl3)δ=157.2,143.1,139.8,139.7,134.3,133.1,131.6,131.5,1 31.2,130.4,128.1,126.9,121.1,113.6,65.8,58.3,45.9,7.2; HRMS(ESI):Exact mass calculated for C 25 H 26 BrNOSe+H + :516.0436,massfound:516.0432.

[0069]

[0070] Synthesis and Spectrum Data of 111:

[0071] 1) Phenylacetylene (5 mmol, 1 equiv.) was weighed into a 100 mL sealed tube with a magnetic stirrer. THF (10 mL) was added under nitrogen atmosphere. After it was fully dissolved at room temperature, the reaction mixture was placed in a low-temperature reaction bath at -78°C and slowly added dropwise with a syringe. n BuLi (1.2 equiv., 2.5 M in THF), the reaction was stirred at -78 ° C for 30 minutes, then Se2Me2 (1.2 equiv.) was added at -78 ° C, the reaction was moved to room temperature for 4 hours, and after the reaction was completed, saturated NH4Cl solution (5 mL) was added to quench the reaction. Extracted with EA (3x 15 mL), the organic phases were combined, dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using PE as the eluent, and the target product methyl (phenylethynyl) selenane was finally obtained with a yield of 90% as a yellow oil.

[0072] 2) Phenylboronic acid (15 mmol, 1 equiv.) was weighed into a 200 mL round-bottom flask with a magnetic stirrer, and anhydrous ethanol (15 mL) was added. After sufficient dissolution, 30% H2O2 (14 equiv.) was added while stirring. The reaction was then stirred at room temperature for 1 minute. After the reaction was completed, water (150 mL) was added to quench the reaction. EA was extracted (3 x 200 mL), and the organic phases were combined, dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The product did not need to be subjected to column chromatography, and the purity could be determined by TLC. 4-(trimethylsilyl)phenol was obtained in almost equivalent reaction as a colorless oil.

[0073] 3) 4-(Trimethylsilyl)phenol (15mmol, 1equiv.) was weighed into a 100mL round-bottom flask with a magnetic stirrer, and tetrabutylammonium bromide (0.1equiv.), NaOH (10equiv.), and DCM (12mL) were added in sequence. The reaction was stirred at room temperature for 30 minutes, and then 1-bromo-2-chloroethane (4equiv.) was added. The reaction was stirred at room temperature for 48 hours. After the reaction was completed, water (10mL) was added to quench the reaction. Extraction with DCM (3x 20mL), the organic phases were combined, the organic phases were dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using PE:EA (20:1) as the eluent, and the target product (4-(2-chloroethoxy)phenyl)trimethylsilane) was finally obtained with a yield of 78% as a colorless oil.

[0074] 4) Weigh (4-(2-chloroethoxy)phenyl)trimethylsilane (3 equiv.) in a 350 mL sealed tube with a magnetic stirrer, add DCM (15 mL) under nitrogen atmosphere, and after it is fully dissolved, add BCl3 (6 equiv., 1 M in DCM). The reaction is stirred at room temperature for 24 hours and then vacuumed for 1 hour to remove the solvent. Then, DCE (15 mL) is added under nitrogen atmosphere. After it is fully dissolved, methyl (phenylethynyl) selenane (3 mmol, 1 equiv.) is added, and the reaction is stirred at room temperature for 12 hours. Then, under nitrogen atmosphere, a mixed solution of pinacol (5 equiv.) and NEt3 (5 equiv.) is added to the reaction tube and reacted at room temperature for 1 hour. After the reaction is completed, MTBE is added to quench the reaction and the solvent is removed by rotary evaporation. The crude product was purified by column chromatography using PE:EA (10:1) as the eluent to obtain the target product (E)-2-(1-(4-(2-chloroethoxy)phenyl)-2-(methylphenylvinyl)-2-phenylvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane as a yellow solid in a yield of 78%.

[0075] 1 H NMR (500MHz, CDCl3) δ = 7.18-7.14 (m, 5H), 6.94 (d, J = 8.7Hz, 2H), 6.61 (d, J = 8.7Hz ,2H),4.11(t,J=6.0Hz,2H),3.73(t,J=6.0Hz,2H),1.76(s,3H),1.37(s,12H)ppm; 13 C NMR (126MHz, CDCl3) δ = 156.3, 141.0, 139.5, 133.8, 130.3, 130.0, 128.0, 126.9, 114.0, 84.2, 67.7, 41.9, 24.8, 6.8ppm; HRMS (ESI): Exact mass calculated for C 23 H 28 BClO3Se+H + :479.1058,mass found:479.1058.

[0076] 5) Weigh (E)-2-(1-(4-(2-chloroethoxy)phenyl)-2-(methylphenylvinyl)-2-phenylvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborane (1 mmol, 1 equiv.), Pd(dppf)2Cl2 (10 mol%) in a 25 mL sealed tube, add THF (5 mL), p-methoxyiodobenzene (2.1 equiv.), KOH (4 equiv.9 M in H2O) under nitrogen atmosphere, then stir the reaction at room temperature for 1 hour, add water (3 mL) after the reaction is completed to quench the reaction. Extract with EA (3 x 10 mL), combine the organic phases, dry the organic phases over anhydrous Na2SO4, and remove the solvent by rotary evaporation. The crude product is directly used for the next step without purification. The obtained crude product (1 equiv.), KI (1 equiv.), dimethylamine hydrochloride (10 equiv.), and K2CO3 (5 equiv.) were weighed into a 25 mL sealed tube with a magnetic stirrer, and DMF (1 mL) was added under a nitrogen atmosphere. The reaction tube was then placed in an oil bath at 100°C and heated and stirred for 12 hours. After the reaction was completed, the temperature was cooled to room temperature and water (3 mL) was added to quench the reaction. EA was extracted (3 x 20 mL), the organic phases were combined, the organic phases were washed with water (3 x 5 mL), the organic phases were dried with anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using DCM:MeOH (50:1) as the eluent, and the target product compound C was finally obtained with a yield of 71% as a white solid with a melting point of 97.5-98.2°C.

[0077] 1 H NMR (500MHz, CDCl3) δ = 7.32 (d, J = 8.5Hz, 2H), 7.27–7.10 (m, 5H), 6.91 (d, J = 8.5Hz, 2H), 6.81 (d, J = 8.5Hz, 2H), 6.55(d,J=8.5Hz,2H),3.94(t,J=5.5Hz,2H),3.82(s,3H),2.68(t,J=5.5Hz,2H),2.31(s,6H),1.62(s,3H)ppm; 13 C NMR (126MHz, CDCl3) δ = 158.6, 156.8, 140.5, 140.1, 136.6, 135.2, 132.1, 131.2, 130.9 ,130.5,128.1,126.7,113.6,113.5,65.5,58.2,55.2,45.8,7.1ppm; HRMS(ESI):Exact mass calculated forC 26 H 29 NO2Se+H +:468.1437,mass found:468.1437.

[0078]

[0079] Synthesis and Spectrum Data of 112:

[0080] 1) Phenylacetylene (5 mmol, 1 equiv.) was weighed into a 100 mL sealed tube with a magnetic stirrer. THF (10 mL) was added under nitrogen atmosphere. After it was fully dissolved at room temperature, the reaction mixture was placed in a low-temperature reaction bath at -78°C and slowly added dropwise with a syringe. n BuLi (1.2 equiv., 2.5 M in THF), the reaction was stirred at -78 ° C for 30 minutes, then Se2Me2 (1.2 equiv.) was added at -78 ° C, the reaction was moved to room temperature for 4 hours, and after the reaction was completed, saturated NH4Cl solution (5 mL) was added to quench the reaction. Extracted with EA (3x 15 mL), the organic phases were combined, dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using PE as the eluent, and the target product methyl (phenylethynyl) selenane was finally obtained with a yield of 90% as a yellow oil.

[0081] 2) Phenylboronic acid (15 mmol, 1 equiv.) was weighed into a 200 mL round-bottom flask with a magnetic stirrer, and anhydrous ethanol (15 mL) was added. After sufficient dissolution, 30% H2O2 (14 equiv.) was added while stirring. The reaction was then stirred at room temperature for 1 minute. After the reaction was completed, water (150 mL) was added to quench the reaction. EA was extracted (3 x 200 mL), and the organic phases were combined, dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The product did not need to be subjected to column chromatography, and the purity could be determined by TLC. 4-(trimethylsilyl)phenol was obtained in almost equivalent reaction as a colorless oil.

[0082] 3) 4-(Trimethylsilyl)phenol (15mmol, 1equiv.) was weighed into a 100mL round-bottom flask with a magnetic stirrer, and tetrabutylammonium bromide (0.1equiv.), NaOH (10equiv.), and DCM (12mL) were added in sequence. The reaction was stirred at room temperature for 30 minutes, and then 1-bromo-2-chloroethane (4equiv.) was added. The reaction was stirred at room temperature for 48 hours. After the reaction was completed, water (10mL) was added to quench the reaction. Extraction with DCM (3x 20mL), the organic phases were combined, the organic phases were dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using PE:EA (20:1) as the eluent, and the target product (4-(2-chloroethoxy)phenyl)trimethylsilane) was finally obtained with a yield of 78% as a colorless oil.

[0083] 4) Weigh (4-(2-chloroethoxy)phenyl)trimethylsilane (3 equiv.) in a 350 mL sealed tube with a magnetic stirrer, add DCM (15 mL) under nitrogen atmosphere, and after it is fully dissolved, add BCl3 (6 equiv., 1 M in DCM). The reaction is stirred at room temperature for 24 hours and then vacuumed for 1 hour to remove the solvent. Then, DCE (15 mL) is added under nitrogen atmosphere. After it is fully dissolved, methyl (phenylethynyl) selenane (3 mmol, 1 equiv.) is added, and the reaction is stirred at room temperature for 12 hours. Then, under nitrogen atmosphere, a mixed solution of pinacol (5 equiv.) and NEt3 (5 equiv.) is added to the reaction tube and reacted at room temperature for 1 hour. After the reaction is completed, MTBE is added to quench the reaction and the solvent is removed by rotary evaporation. The crude product was purified by column chromatography using PE:EA (10:1) as the eluent to obtain the target product (E)-2-(1-(4-(2-chloroethoxy)phenyl)-2-(methylphenylvinyl)-2-phenylvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane as a yellow solid in a yield of 78%.

[0084] 1 H NMR (500MHz, CDCl3) δ = 7.18-7.14 (m, 5H), 6.94 (d, J = 8.7Hz, 2H), 6.61 (d, J = 8.7Hz ,2H),4.11(t,J=6.0Hz,2H),3.73(t,J=6.0Hz,2H),1.76(s,3H),1.37(s,12H)ppm; 13 C NMR (126MHz, CDCl3) δ = 156.3, 141.0, 139.5, 133.8, 130.3, 130.0, 128.0, 126.9, 114.0, 84.2, 67.7, 41.9, 24.8, 6.8ppm; HRMS (ESI): Exact mass calculated for C 23 H 28 BClO3Se+H + :479.1058,mass found:479.1058.

[0085] 5) Weigh (E)-2-(1-(4-(2-chloroethoxy)phenyl)-2-(methylphenylvinyl)-2-phenylvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborane (1 mmol, 1 equiv.), Pd(dppf)2Cl2 (10 mol%) in a 25 mL sealed tube, add THF (5 mL), iodobenzene (2.1 equiv.), KOH (4 equiv. 9 M in H2O) under nitrogen atmosphere, then stir the reaction at room temperature for 1 hour, add water (3 mL) after the reaction is completed to quench the reaction. Extract with EA (3 x 10 mL), combine the organic phases, dry the organic phases over anhydrous Na2SO4, and remove the solvent by rotary evaporation. The obtained crude product does not need to be purified and is directly used in the next step. The crude product (1 equiv.), KI (1 equiv.), dimethylamine hydrochloride (10 equiv.), and K2CO3 (5 equiv.) were weighed into a 25 mL sealed tube with a magnetic stirrer. DMF (1 mL) was added under a nitrogen atmosphere, and the reaction tube was then placed in an oil bath at 100°C and heated with stirring for 12 hours. After the reaction was completed, the temperature was cooled to room temperature and water (3 mL) was added to quench the reaction. EA was used for extraction (3 x 20 mL), the organic phases were combined, the organic phases were washed with water (3 x 5 mL), the organic phases were dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using DCM:MeOH (50:1) as the eluent, and the target product, compound 112, was finally obtained in a yield of 67% as a yellow solid with a melting point of 91.5-92.4°C.

[0086] 1 H NMR (500MHz, CDCl3) δ = 7.41-7.28 (m, 5H), 7.28-7.10 (m, 5H), 6.82 (d, J = 8.5Hz, 2H), 6.55 (d ,J=8.5Hz,2H),3.93(t,J=5.5Hz,2H),2.67(t,J=5.5Hz,2H),2.30(s,6H),1.62(s,3H)ppm; 13 C NMR(126MHz, CDCl3)δ=156.9,144.2,140.9,139.9,134.7,132.5,131.1,130.5,129 .6,128.3,128.1,127.1,126.8,113.5,65.5,58.0,45.7,7.1ppm; HRMS(ESI):Exact mass calculated for C 25 H 27 NOSe+H + :438.1331,mass found:438.1326.

[0087]

[0088] Synthesis and Spectrum Data of 114:

[0089] 1) Weigh 1-ethynyl-4-isopropylbenzene (3 mmol, 1 equiv.) into a 50 mL sealed tube with a magnetic stirrer, add THF (6 mL) under nitrogen atmosphere, and after fully dissolving at room temperature, place the above reaction tube in a low-temperature reaction bath at -78°C and slowly add dropwise with a syringe. n BuLi (1.2 equiv., 2.5 M in THF), the reaction was stirred at -78 ° C for 30 minutes, then Se2Me2 (1.2 equiv.) was added at -78 ° C, the reaction was moved to room temperature for 4 hours, and after the reaction was completed, saturated NH4Cl solution (3 mL) was added to quench the reaction. Extraction with EA (3 x 10 mL), the organic phases were combined, the organic phases were dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using PE as the eluent, and the target product ((4-isopropylphenyl)ethynyl)(methyl)selenane was finally obtained with a yield of 89% as a yellow oil.

[0090] 2) Phenylboronic acid (12 mmol, 1 equiv.) was weighed into a 200 mL round-bottom flask with a magnetic stirrer, and anhydrous ethanol (15 mL) was added. After sufficient dissolution, 30% H2O2 (14 equiv.) was added while stirring. The reaction was then stirred at room temperature for 1 minute. After the reaction was completed, water (120 mL) was added to quench the reaction. EA was extracted (3 x 160 mL), and the organic phases were combined, dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The product did not need to be subjected to column chromatography, and the purity could be determined by TLC. 4-(trimethylsilyl)phenol was obtained in almost equivalent reaction as a colorless oil.

[0091] 3) 4-(Trimethylsilyl)phenol (12 mmol, 1 equiv.) was weighed into a 100 mL round-bottom flask with a magnetic stirrer, and tetrabutylammonium bromide (0.1 equiv.), NaOH (10 equiv.), and DCM (12 mL) were added in sequence. The reaction was stirred at room temperature for 30 minutes, and then 1-bromo-2-chloroethane (4 equiv.) was added. The reaction was stirred at room temperature for 48 hours. After the reaction was completed, water (10 mL) was added to quench the reaction. Extraction with DCM (3 x 20 mL), the organic phases were combined, the organic phases were dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using PE:EA (20:1) as the eluent, and the target product (4-(2-chloroethoxy)phenyl)trimethylsilane) was finally obtained with a yield of 78% as a colorless oil.

[0092] 4) Weigh (4-(2-chloroethoxy)phenyl)trimethylsilane (3 equiv.) in a 250 mL sealed tube with a magnetic stirrer, add DCM (10 mL) under nitrogen atmosphere, and after sufficient dissolution, add BCl3 (6 equiv., 1 M in DCM), and then stir the reaction at room temperature for 24 hours. Then, vacuum the mixture for 1 hour to remove the solvent. Then, add DCE (10 mL) under nitrogen, and after sufficient dissolution, add ((4-isopropylphenyl)ethynyl)(methyl)selenane (2 mmol, 1 equiv.), and stir the reaction at room temperature for 12 hours. Then, under nitrogen atmosphere, add a mixed solution of pinacol (5 equiv.) and NEt3 (5 equiv.) to the tube, and react at room temperature for 1 hour. After the reaction is completed, add MTBE to quench the reaction, and remove the solvent by rotary evaporation. The crude product was purified by column chromatography using PE:EA (10:1) as the eluent to obtain the target product (E)-2-(1-(4-(2-chloroethoxy)phenyl)-2-(4-isopropylphenyl)-2-(methylpropenyl)vinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane as a white solid in a yield of 76%.

[0093] 1 H NMR (500MHz, CDCl3) δ = 7.08 (d, J = 8.5Hz, 2H), 7.01 (d, J = 8.5Hz, 2H), 6.94 (d, J = 8.5Hz, 2H), 6.61 (d, J = 8.5Hz, 2H), 4. 11(t,J=6.0Hz,2H),3.72(t,J=6.0Hz,2H),2.86–2.77(m,1H),1.77(s,3H),1.37(s,12H),1.19(d,J=7.0Hz,6H)ppm; 13 C NMR (126MHz, CDCl3) δ = 156.2, 147.6, 140.9, 136.8, 134.0, 130.3, 130.0, 125.9, 114.0, 84.1, 67.8, 41.9, 33.7, 24.8, 23.9, 6.9ppm; HRMS (ESI): Exact mass calculated for C 26 H 34 BClO3Se+H + :521.1528,mass found:521.1529.

[0094] 5) Weigh (E)-2-(1-(4-(2-chloroethoxy)phenyl)-2-(4-isopropylphenyl)-2-(methylpropenyl)vinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1 mmol, 1 equiv.), Pd(dppf)2Cl2 (10 mol%) in a 25 mL sealed tube, add THF (5 mL), 1-iodo-4-(methoxymethoxy)benzene (2.1 equiv.), KOH (4 equiv. 9 M in H2O) under nitrogen atmosphere, then stir the reaction at room temperature for 1 hour, add water (3 mL) after the reaction is completed to quench the reaction. Extract with EA (3 x 10 mL), combine the organic phases, dry the organic phases over anhydrous Na2SO4, and remove the solvent by rotary evaporation. The crude product is directly used for the next step without purification. The crude product (1 equiv.), KI (1 equiv.), dimethylamine hydrochloride (10 equiv.), and K2CO3 (5 equiv.) were weighed into a 25 mL sealed tube with a magnetic stirrer. DMF (1 mL) was added under nitrogen atmosphere, and then the reaction tube was placed in an oil bath at 100°C and heated with stirring for 12 hours. After the reaction was completed, the temperature was cooled to room temperature and water (3 mL) was added to quench the reaction. EA was extracted (3 x 20 mL), the organic phases were combined, washed with water (3 x 5 mL), dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using DCM:MeOH (50:1) as the eluent to obtain the target product 114 as a yellow oil with a yield of 70%.

[0095] 1 H NMR (500MHz, CDCl3) δ=7.31(d,J=8.5Hz,2H),7.14(d,J=8.0Hz,2H),7.07(d,J=8.0Hz,2H),7.03(d,J=8.5Hz,2H),6.81(d,J=8.5Hz,2H),6.55(d,J=8 .5Hz,2H),5.20(s,2H),3.93(t,J=5.5Hz,2H),3.50(s,3H),2.84(m,1H),2 .65(t,J=5.5Hz,2H),2.29(s,6H),1.62(s,3H),1.21(d,J=7.5Hz,6H)ppm; 13C NMR (126MHz, CDCl3) δ = 156.8, 156.3, 147.4, 140.1, 138.0, 137.3, 135.2, 132.5, 131.2, 131.0, 1 30.4,126.0,115.9,113.4,94.5,65.7,58.2,56.1,45.8,33.7,23.9,7.1ppm; HRMS(ESI):Exact mass calculated forC 30 H 37 NO3Se+H + :540.2012,mass found:540.2013.

[0096]

[0097] Synthesis and Spectrum Data of 113:

[0098] Compound 114 (0.1 mmol, 1 equiv.) was weighed into a 50 mL round-bottom flask with a magnetic stirrer, followed by methanol (1 mL), and concentrated hydrochloric acid (10 equiv.) was added while stirring, and the reaction was stirred at room temperature for 3 hours. After the reaction was completed, the solvent was directly removed by rotary evaporation, and the crude product was purified by column chromatography using DCM:MeOH (10:1) as the eluent, and the target product 113 was finally obtained with a yield of 64% as a yellow solid with a melting point of 122.2-122.9°C.

[0099] 1 H NMR (500MHz, MeOD) δ = 7.06 (m, 6H), 6.80 (d, J = 7.5Hz, 2H), 6.71 (d, J = 8.0Hz, 2H), 6.61 (d, J = 8.0Hz, 2H), 4 .24(s,2H),3.52(s,2H),3.26(s,1H),2.87(s,6H),2.77(m,1H),1.50(s,3H),1.15(d,J=6.5Hz,6H)ppm; 13 C NMR(126MHz,MeOD)δ=156.2,155.7,147.3,140.1,137.6,136.8,135.4,132.4,131.1,13 0.7,130.3,125.7,114.6,113.3,61.7,56.5,42.8,33.6,23.0,5.5ppm; HRMS(ESI):Exact mass calculated for C 28 H 33 NO2Se+H +:496.1750,mass found:496.1751.

[0100]

[0101] Synthesis and spectral data of 115:

[0102] 1) Weigh 1-ethynyl-4-methoxybenzene (3 mmol, 1 equiv.) into a 50 mL sealed tube with a magnetic stirrer, add THF (6 mL) under nitrogen atmosphere, and after fully dissolving at room temperature, place the above reaction tube into a low-temperature reaction bath at -78°C and slowly add dropwise with a syringe n BuLi (1.2 equiv., 2.5 M in THF), the reaction was stirred at -78 ° C for 30 minutes, then Se2Me2 (1.2 equiv.) was added at -78 ° C, the reaction was moved to room temperature for 4 hours, and after the reaction was completed, saturated NH4Cl solution (3 mL) was added to quench the reaction. Extraction with EA (3 x 10 mL), the organic phases were combined, the organic phases were dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using PE as the eluent, and the target product ((4-methoxyphenyl)ethynyl)(methyl)selenane was finally obtained with a yield of 91% as a yellow oil.

[0103] 2) Phenylboronic acid (12 mmol, 1 equiv.) was weighed into a 200 mL round-bottom flask with a magnetic stirrer, and anhydrous ethanol (15 mL) was added. After sufficient dissolution, 30% H2O2 (14 equiv.) was added while stirring. The reaction was then stirred at room temperature for 1 minute. After the reaction was completed, water (120 mL) was added to quench the reaction. EA was extracted (3 x 160 mL), and the organic phases were combined, dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The product did not need to be subjected to column chromatography, and the purity could be determined by TLC. 4-(trimethylsilyl)phenol was obtained in almost equivalent reaction as a colorless oil.

[0104] 3) 4-(Trimethylsilyl)phenol (12 mmol, 1 equiv.) was weighed into a 100 mL round-bottom flask with a magnetic stirrer, and tetrabutylammonium bromide (0.1 equiv.), NaOH (10 equiv.), and DCM (12 mL) were added in sequence. The reaction was stirred at room temperature for 30 minutes, and then 1-bromo-2-chloroethane (4 equiv.) was added. The reaction was stirred at room temperature for 48 hours. After the reaction was completed, water (10 mL) was added to quench the reaction. Extraction with DCM (3 x 20 mL), the organic phases were combined, the organic phases were dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using PE:EA (20:1) as the eluent, and the target product (4-(2-chloroethoxy)phenyl)trimethylsilane) was finally obtained with a yield of 78% as a colorless oil.

[0105] 4) Weigh (4-(2-chloroethoxy)phenyl)trimethylsilane (3 equiv.) in a 250 mL sealed tube with a magnetic stirrer, add DCM (10 mL) under nitrogen atmosphere, and after sufficient dissolution, add BCl3 (6 equiv., 1 M in DCM), and then stir the reaction at room temperature for 24 hours. Then, vacuum the mixture for 1 hour to remove the solvent. Then, add DCE (10 mL) under nitrogen, and after sufficient dissolution, add ((4-methoxyphenyl)ethynyl)(methyl)selenane (2 mmol, 1 equiv.), and stir the reaction at room temperature for 12 hours. Then, under nitrogen atmosphere, add a mixed solution of pinacol (5 equiv.) and NEt3 (5 equiv.) to the tube, and react at room temperature for 1 hour. After the reaction is completed, add MTBE to quench the reaction, and remove the solvent by rotary evaporation. The crude product was purified by column chromatography using PE:EA (10:1) as the eluent to obtain the target product ((E)-2-(1-(4-(2-chloroethoxy)phenyl)-2-(4-methoxyphenyl)-2-(methylpropenyl)vinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane) as a white solid in a yield of 75%.

[0106] 1 H NMR(500MHz,Chloroform-d)δ7.10(d,J=8.7Hz,2H),6.95(d,J=8.7Hz,2H),6.69(d,J=8.7Hz,2H) ,6.63(d,J=8.8Hz,2H),4.12(t,J=5.9Hz,2H),3.76-3.72(m,5H),1.78(s,3H),1.36(s,12H)ppm; 13C NMR (126MHz, CDCl3) δ = 158.4, 156.2, 140.8, 134.1, 131.7, 131.4, 130.3, 114.1, 113.4, 84.1, 67.8, 55.1, 41.9, 24.8, 6.8ppm; HRMS (ESI): Exactmass calculated for C 24 H 30 BClO4Se+H + :509.1164,mass found:509.1162.

[0107] 5) ((E)-2-(1-(4-(2-chloroethoxy)phenyl)-2-(4-methoxyphenyl)-2-(methylpropenyl)vinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1 mmol, 1 equiv.), Pd(dppf)2Cl2 (10 mol%) were weighed into a 25 mL sealed tube, THF (5 mL), 1-iodo-4-(methoxymethoxy)benzene (2.1 equiv.), KOH (4 equiv. 9 M in H2O) were added under nitrogen atmosphere, and the reaction was stirred at room temperature for 1 hour. After the reaction was completed, water (3 mL) was added to quench the reaction. The mixture was extracted with EA (3x 10mL), the organic phases were combined, the organic phases were dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was directly used in the next step without purification. The crude product (1equiv.), KI (1equiv.), dimethylamine hydrochloride (10equiv.), and K2CO3 (5equiv.) were weighed in a 25mL sealed tube with a magnetic stirrer, and DMF (1mL) was added under a nitrogen atmosphere. The reaction tube was then placed in an oil bath at 100°C and heated with stirring for 12 hours. After the reaction was completed, the mixture was cooled to room temperature and water (3mL) was added to quench the reaction. EA was used for extraction (3x 20mL), the organic phases were combined, the organic phases were washed with water (3x 5mL), the organic phases were dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using DCM:MeOH (50:1) as the eluent, and the target product compound 115 was finally obtained with a yield of 72% as a white solid with a melting point of 80.2-81.0°C. 1H NMR (500MHz, CDCl3) δ = 7.30 (d, J = 8.5Hz, 2H), 7.15 (d, J = 8.5Hz, 2H), 7.02 (d, J = 8.5Hz, 2H), 6.81 (d, J = 8.5Hz, 2H), 6.75 (d, J = 8.5Hz, 2H), 6.56(d,J=8.5Hz,2H),5.19(s,2H),3.94(t,J=5.5Hz,2H),3.77(s,3H),3.50(s,3H),2.67(t,J=5.5Hz,2H),2.30(s,6H),1.64(s,3H)ppm; 13 C NMR (126MHz, CDCl3) δ = 158.2, 156.8, 156.3, 140.1, 138.0, 135.3, 132.4, 132.2, 131.7, 131.2 ,130.9,115.9,113.5,113.4,94.5,65.6,58.2,56.1,55.1,45.8,7.1; HRMS(ESI):Exactmass calculated for C 28 H 33 NO4Se+H + :528.1648,mass found:528.1653.

[0108]

[0109] Synthesis and Spectrum Data of 116:

[0110] 1) Phenylacetylene (5 mmol, 1 equiv.) was weighed into a 100 mL sealed tube with a magnetic stirrer. THF (10 mL) was added under nitrogen atmosphere. After it was fully dissolved at room temperature, the reaction mixture was placed in a low-temperature reaction bath at -78°C and slowly added dropwise with a syringe. n BuLi (1.2 equiv., 2.5 M in THF), the reaction was stirred at -78 ° C for 30 minutes, then Se2Me2 (1.2 equiv.) was added at -78 ° C, the reaction was moved to room temperature for 4 hours, and after the reaction was completed, saturated NH4Cl solution (5 mL) was added to quench the reaction. Extracted with EA (3x 15 mL), the organic phases were combined, dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using PE as the eluent, and the target product methyl (phenylethynyl) selenane was finally obtained with a yield of 90% as a yellow oil.

[0111] 2) Phenylboronic acid (15 mmol, 1 equiv.) was weighed into a 200 mL round-bottom flask with a magnetic stirrer, and anhydrous ethanol (15 mL) was added. After sufficient dissolution, 30% H2O2 (14 equiv.) was added while stirring. The reaction was then stirred at room temperature for 1 minute. After the reaction was completed, water (150 mL) was added to quench the reaction. EA was extracted (3 x 200 mL), and the organic phases were combined, dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The product did not need to be subjected to column chromatography, and the purity could be determined by TLC. 4-(trimethylsilyl)phenol was obtained in almost equivalent reaction as a colorless oil.

[0112] 3) 4-(Trimethylsilyl)phenol (15mmol, 1equiv.) was weighed into a 100mL round-bottom flask with a magnetic stirrer, and tetrabutylammonium bromide (0.1equiv.), NaOH (10equiv.), and DCM (12mL) were added in sequence. The reaction was stirred at room temperature for 30 minutes, and then 1-bromo-2-chloroethane (4equiv.) was added. The reaction was stirred at room temperature for 48 hours. After the reaction was completed, water (10mL) was added to quench the reaction. Extraction with DCM (3x 20mL), the organic phases were combined, the organic phases were dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using PE:EA (20:1) as the eluent, and the target product (4-(2-chloroethoxy)phenyl)trimethylsilane) was finally obtained with a yield of 78% as a colorless oil.

[0113] 4) Weigh (4-(2-chloroethoxy)phenyl)trimethylsilane (3 equiv.) in a 350 mL sealed tube with a magnetic stirrer, add DCM (15 mL) under nitrogen atmosphere, and after it is fully dissolved, add BCl3 (6 equiv., 1 M in DCM). The reaction is stirred at room temperature for 24 hours and then vacuumed for 1 hour to remove the solvent. Then, DCE (15 mL) is added under nitrogen atmosphere. After it is fully dissolved, methyl (phenylethynyl) selenane (3 mmol, 1 equiv.) is added, and the reaction is stirred at room temperature for 12 hours. Then, under nitrogen atmosphere, a mixed solution of pinacol (5 equiv.) and NEt3 (5 equiv.) is added to the reaction tube and reacted at room temperature for 1 hour. After the reaction is completed, MTBE is added to quench the reaction and the solvent is removed by rotary evaporation. The crude product was purified by column chromatography using PE:EA (10:1) as the eluent to obtain the target product (E)-2-(1-(4-(2-chloroethoxy)phenyl)-2-(methylphenylvinyl)-2-phenylvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane as a yellow solid in a yield of 78%.

[0114] 1H NMR (500MHz, CDCl3) δ = 7.18-7.14 (m, 5H), 6.94 (d, J = 8.7Hz, 2H), 6.61 (d, J = 8.7Hz ,2H),4.11(t,J=6.0Hz,2H),3.73(t,J=6.0Hz,2H),1.76(s,3H),1.37(s,12H)ppm; 13 C NMR (126MHz, CDCl3) δ = 156.3, 141.0, 139.5, 133.8, 130.3, 130.0, 128.0, 126.9, 114.0, 84.2, 67.7, 41.9, 24.8, 6.8ppm; HRMS (ESI): Exact mass calculated for C 23 H 28 BClO3Se+H + :479.1058,mass found:479.1058.

[0115] 5) Weigh (E)-2-(1-(4-(2-chloroethoxy)phenyl)-2-(methylphenylvinyl)-2-phenylvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborane (1 mmol, 1 equiv.), Pd(dppf)2Cl2 (10 mol%) in a 25 mL sealed tube, add THF (5 mL), iodobenzene (2.1 equiv.), KOH (4 equiv. 9 M in H2O) under nitrogen atmosphere, then stir the reaction at room temperature for 1 hour, add water (3 mL) after the reaction is completed to quench the reaction. Extract with EA (3 x 10 mL), combine the organic phases, dry the organic phases over anhydrous Na2SO4, and remove the solvent by rotary evaporation. The obtained crude product does not need to be purified and is directly used in the next step. The crude product (1 equiv.), KI (1 equiv.), diethylamine (10 equiv.), and K2CO3 (5 equiv.) were weighed into a 25 mL sealed tube with a magnetic stirrer. DMF (1 mL) was added under a nitrogen atmosphere, and the reaction tube was then placed in an oil bath at 100°C and heated with stirring for 12 hours. After the reaction was completed, the temperature was cooled to room temperature and water (3 mL) was added to quench the reaction. EA was used for extraction (3 x 20 mL), the organic phases were combined, the organic phases were washed with water (3 x 5 mL), the organic phases were dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using DCM:MeOH (50:1) as the eluent, and the target product, compound 116, was finally obtained in a yield of 62% as a white solid with a melting point of 124.9-125.7°C.

[0116] 1H NMR (500MHz, CDCl3) δ = 7.46-7.39 (m, 4H), 7.36-7.24 (m, 5H), 7.21-7.15 (m, 1H), 6.86 (d, J = 8.4Hz, 2H), 6.58 (d, J = 8. 4Hz,2H),3.93(t,J=6.4Hz,2H),2.81(t,J=6.4Hz,2H),2.61(q,J=7.1Hz,4H),1.66(s,3H),1.05(t,J=7.1Hz,6H)ppm; 13 C NMR(126MHz, CDCl3)δ=157.0,144.3,141.0,140.0,134.6,132.4,131.2,130.5,129.7 ,128.3,128.1,127.1,126.8,113.5,66.3,51.7,47.8,11.9,7.1ppm; HRMS(ESI):Exact masscalculated for C 27 H 31 NOSe+H + :466.1644,mass found:466.1639.

[0117]

[0118] Synthesis and spectral data of 117:

[0119] 1) Phenyl acetylene (5 mmol, 1 equiv.) was weighed into a 100 mL sealed tube with a magnetic stirrer. THF (10 mL) was added under nitrogen atmosphere. After it was fully dissolved at room temperature, the reaction tube was placed in a low-temperature reaction bath at -78°C and slowly added dropwise with a syringe. n BuLi (1.2 equiv., 2.5 M in THF), the reaction was stirred at -78 ° C for 30 minutes, then Se2Me2 (1.2 equiv.) was added at -78 ° C, the reaction was moved to room temperature for 4 hours, and after the reaction was completed, saturated NH4Cl solution (5 mL) was added to quench the reaction. Extracted with EA (3x 15 mL), the organic phases were combined, dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using PE as the eluent, and the target product methyl (phenylethynyl) selenane was finally obtained with a yield of 90% as a yellow oil.

[0120] 2) Phenylboronic acid (15 mmol, 1 equiv.) was weighed into a 200 mL round-bottom flask with a magnetic stirrer, and anhydrous ethanol (15 mL) was added. After sufficient dissolution, 30% H2O2 (14 equiv.) was added while stirring. The reaction was then stirred at room temperature for 1 minute. After the reaction was completed, water (150 mL) was added to quench the reaction. EA was extracted (3 x 200 mL), and the organic phases were combined, dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The product did not need to be subjected to column chromatography, and the purity could be determined by TLC. 4-(trimethylsilyl)phenol was obtained in almost equivalent reaction as a colorless oil.

[0121] 3) 4-(Trimethylsilyl)phenol (15 mmol, 1 equiv.) was weighed into a 100 mL round-bottom flask with a magnetic stirrer, and tetrabutylammonium bromide (0.1 equiv.), NaOH (10 equiv.), and DCM (12 mL) were added in sequence. The reaction was stirred at room temperature for 30 minutes, and then 1-bromo-2-chloroethane (4 equiv.) was added. The reaction was stirred at room temperature for 48 hours. After the reaction was completed, water (10 mL) was added to quench the reaction. Extraction with DCM (3 x 20 mL), the organic phases were combined, dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using PE:EA (20:1) as the eluent, and the target product (4-(2-chloroethoxy)phenyl)trimethylsilane) was finally obtained with a yield of 78% as a colorless oil.

[0122] 4) Weigh (4-(2-chloroethoxy)phenyl)trimethylsilane (3 equiv.) in a 350 mL sealed tube with a magnetic stirrer, add DCM (15 mL) under nitrogen atmosphere, and after sufficient dissolution, add BCl3 (6 equiv., 1 M in DCM), and then stir the reaction at room temperature for 24 hours. Then vacuum for 1 hour to remove the solvent. Then add DCE (15 mL) under nitrogen, and after sufficient dissolution, add methyl (phenylethynyl) selenane (3 mmol, 1 equiv.), and stir the reaction at room temperature for 12 hours. Then, under nitrogen atmosphere, add a mixed solution of pinacol (5 equiv.) and NEt3 (5 equiv.) to the tube, and react at room temperature for 1 hour. After the reaction is completed, add MTBE to quench the reaction and remove the solvent by rotary evaporation. The crude product was purified by column chromatography using PE:EA (10:1) as the eluent to obtain the target product (E)-2-(1-(4-(2-chloroethoxy)phenyl)-2-(methylphenylvinyl)-2-phenylvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane as a yellow solid in a yield of 78%.

[0123] 1H NMR (500MHz, CDCl3) δ = 7.18-7.14 (m, 5H), 6.94 (d, J = 8.7Hz, 2H), 6.61 (d, J = 8.7Hz ,2H),4.11(t,J=6.0Hz,2H),3.73(t,J=6.0Hz,2H),1.76(s,3H),1.37(s,12H)ppm; 13 C NMR (126MHz, CDCl3) δ = 156.3, 141.0, 139.5, 133.8, 130.3, 130.0, 128.0, 126.9, 114.0, 84.2, 67.7, 41.9, 24.8, 6.8ppm; HRMS (ESI): Exact mass calculated for C 23 H 28 BClO3Se+H + :479.1058,mass found:479.1058.

[0124] 5) Weigh (E)-2-(1-(4-(2-chloroethoxy)phenyl)-2-(methylphenylvinyl)-2-phenylvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborane (1 mmol, 1 equiv.), Pd(dppf)2Cl2 (10 mol%) in a 25 mL sealed tube, add THF (5 mL), p-bromoiodobenzene (2.1 equiv.), KOH (4 equiv.9 M in H2O) under nitrogen atmosphere, then stir the reaction at room temperature for 1 hour, add water (3 mL) after the reaction is completed to quench the reaction. Extract with EA (3 x 10 mL), combine the organic phases, dry the organic phases over anhydrous Na2SO4, and remove the solvent by rotary evaporation. The crude product is directly used for the next step without purification. The crude product (1 equiv.) was weighed into a 25 mL sealed tube with a magnetic stirrer, and tetrahydropyrrole (45 equiv.) was added under nitrogen atmosphere, and then the reaction tube was placed in an oil bath at 80°C and heated with stirring for 12 hours. After the reaction was completed, the temperature was cooled to room temperature and water (3 mL) was added to quench the reaction. It was extracted with EA (3 x 20 mL), the organic phases were combined, washed with water (3 x 5 mL), dried with anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using DCM:MeOH (50:1) as the eluent, and the target product compound 117 was finally obtained with a yield of 61% as a white solid with a melting point of 124.2-125.3°C.

[0125] 1H NMR (500MHz, CDCl3) δ = 7.50 (d, J = 8.0Hz, 2H), 7.28 (d, J = 8.0Hz, 2H), 7.25-7.20 (m, 4H), 7.17-7.12 (m, 1H), 6.78 (d, J = 8. 0Hz,2H),6.55(d,J=8.0Hz,2H),3.96(t,J=6.0Hz,2H),2.80(t,J=6.0Hz,2H),2.56(s,4H),1.77(s,4H),1.63(s,3H)ppm; 13 C NMR (126MHz, CDCl3) δ=157.2,143.1,139.8,139.7,134.3,133.1,131.6,131.5,131.2 ,130.4,128.2,126.9,121.1,113.7,66.9,55.1,54.7,23.5,7.2ppm; HRMS(ESI):Exact masscalculated for C 27 H 28 BrNOSe+H + :542.0592,mass found:542.0591.

[0126]

[0127] Synthesis and Spectrum Data of 118:

[0128] 1) Phenylacetylene (5 mmol, 1 equiv.) was weighed into a 100 mL sealed tube with a magnetic stirrer. THF (10 mL) was added under nitrogen atmosphere. After fully dissolved at room temperature, the reaction was placed in a low temperature reaction bath at -78°C. nBuLi (1.2 equiv., 2.5 M in THF) was slowly added dropwise with a syringe. The reaction was stirred at -78°C for 30 minutes. Se2Me2 (1.2 equiv.) was then added at -78°C. The reaction was moved to room temperature for 4 hours. After the reaction was completed, saturated NH4Cl solution (5 mL) was added to quench the reaction. The mixture was extracted with EA (3 x 15 mL), the organic phases were combined, dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using PE as the eluent, and the target product methyl (phenylethynyl) selenane was finally obtained with a yield of 90% as a yellow oil.

[0129] 2) Phenylboronic acid (15 mmol, 1 equiv.) was weighed into a 200 mL round-bottom flask with a magnetic stirrer, and anhydrous ethanol (15 mL) was added. After sufficient dissolution, 30% H2O2 (14 equiv.) was added while stirring. The reaction was then stirred at room temperature for 1 minute. After the reaction was completed, water (150 mL) was added to quench the reaction. EA was extracted (3 x 200 mL), and the organic phases were combined, dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The product did not need to be subjected to column chromatography, and the purity could be determined by TLC. 4-(trimethylsilyl)phenol was obtained in almost equivalent reaction as a colorless oil.

[0130] 3) 4-(Trimethylsilyl)phenol (15mmol, 1equiv.) was weighed into a 100mL round-bottom flask with a magnetic stirrer, and tetrabutylammonium bromide (0.1equiv.), NaOH (10equiv.), and DCM (12mL) were added in sequence. The reaction was stirred at room temperature for 30 minutes, and then 1-bromo-2-chloroethane (4equiv.) was added. The reaction was stirred at room temperature for 48 hours. After the reaction was completed, water (10mL) was added to quench the reaction. Extraction with DCM (3x 20mL), the organic phases were combined, the organic phases were dried over anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using PE:EA (20:1) as the eluent, and the target product (4-(2-chloroethoxy)phenyl)trimethylsilane) was finally obtained with a yield of 78% as a colorless oil.

[0131] 4) Weigh (4-(2-chloroethoxy)phenyl)trimethylsilane (3 equiv.) in a 350 mL sealed tube with a magnetic stirrer, add DCM (15 mL) under nitrogen atmosphere, and after it is fully dissolved, add BCl3 (6 equiv., 1 M in DCM). The reaction is stirred at room temperature for 24 hours and then vacuumed for 1 hour to remove the solvent. Then, DCE (15 mL) is added under nitrogen atmosphere. After it is fully dissolved, methyl (phenylethynyl) selenane (3 mmol, 1 equiv.) is added, and the reaction is stirred at room temperature for 12 hours. Then, under nitrogen atmosphere, a mixed solution of pinacol (5 equiv.) and NEt3 (5 equiv.) is added to the reaction tube and reacted at room temperature for 1 hour. After the reaction is completed, MTBE is added to quench the reaction and the solvent is removed by rotary evaporation. The crude product was purified by column chromatography using PE:EA (10:1) as the eluent to obtain the target product (E)-2-(1-(4-(2-chloroethoxy)phenyl)-2-(methylphenylvinyl)-2-phenylvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane as a yellow solid in a yield of 78%.

[0132] 1H NMR (500MHz, CDCl3) δ = 7.18-7.14 (m, 5H), 6.94 (d, J = 8.7Hz, 2H), 6.61 (d, J = 8.7Hz ,2H),4.11(t,J=6.0Hz,2H),3.73(t,J=6.0Hz,2H),1.76(s,3H),1.37(s,12H)ppm; 13 C NMR (126MHz, CDCl3) δ = 156.3, 141.0, 139.5, 133.8, 130.3, 130.0, 128.0, 126.9, 114.0, 84.2, 67.7, 41.9, 24.8, 6.8ppm; HRMS (ESI): Exact mass calculated for C 23 H 28 BClO3Se+H + :479.1058,mass found:479.1058.

[0133] 5) Weigh (E)-2-(1-(4-(2-chloroethoxy)phenyl)-2-(methylphenylvinyl)-2-phenylvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborane (1 mmol, 1 equiv.), Pd(dppf)2Cl2 (10 mol%) in a 25 mL sealed tube, add THF (5 mL), 1,4-diiodobenzene (2.1 equiv.), KOH (4 equiv. 9 M in H2O) under nitrogen atmosphere, then stir the reaction at room temperature for 1 hour, add water (3 mL) after the reaction is completed to quench the reaction. Extract with EA (3 x 10 mL), combine the organic phases, dry the organic phases over anhydrous Na2SO4, and remove the solvent by rotary evaporation. The obtained crude product does not need to be purified and is directly used in the next step. The crude product (1 equiv.) was weighed into a 25 mL sealed tube with a magnetic stirrer, and tetrahydropyrrole (45 equiv.) was added under nitrogen atmosphere. The reaction tube was then placed in an oil bath at 80°C and heated with stirring for 12 hours. After the reaction was completed, the temperature was cooled to room temperature and water (3 mL) was added to quench the reaction. It was extracted with EA (3 x 20 mL), the organic phases were combined, washed with water (3 x 5 mL), dried with anhydrous Na2SO4, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography using DCM:MeOH (50:1) as the eluent to obtain the target product 118 in a yield of 53% as a white solid with a melting point of 128.8-131.0°C. 1H NMR (500MHz, CDCl3) δ = 7.70 (d, J = 8.0Hz, 2H), 7.25-7.20 (m, 4H), 7.15 (d, J = 8.0Hz, 3H), 6.78 (d, J = 9.0Hz, 2H), 6.55(d,J=9.0Hz,2H),3.96(t,J=6.0Hz,2H),2.80(t,J=6.0Hz,2H),2.56(s,4H),1.77(s,4H),1.63(s,3H)ppm; 13 C NMR (126MHz, CDCl3) δ=157.2,143.8,139.9,139.7,137.5,134.2,133.1,131.8,131.2 ,130.4,128.2,126.9,113.7,92.8,66.9,55.1,54.7,23.5,7.2ppm; HRMS(ESI):Exact mass calculated for C 27 H 28 INOSe+H + :590.0454,massfound:590.0454.

[0134]

[0135]

[0136] Synthesis and spectral data of 119:

[0137] Compound 109 (0.1 mmol, 1 equiv.) was weighed into a 50 mL round-bottom flask with a magnetic stirrer, followed by methanol (1 mL), and concentrated hydrochloric acid (10 equiv.) was added while stirring, and the reaction was stirred at room temperature for 3 hours. After the reaction was completed, the solvent was directly removed by rotary evaporation, and the crude product was purified by column chromatography using DCM:MeOH (10:1) as the eluent, and the target product compound J was finally obtained with a yield of 63% as a white solid with a melting point of 133.1-133.9°C.

[0138] 1 H NMR (500MHz, MeOD) δ = 7.19–7.06 (m, 7H), 6.82 (d, J = 8.5Hz, 2H), 6.73 (d, J = 8.5Hz, 2H), 6. 62(d,J=8.5Hz,2H),4.15(s,2H),3.47(s,2H),3.27(s,1H),2.87(s,6H),1.52(s,3H)ppm; 13C NMR(126MHz,MeOD)δ=156.2,155.7,140.4,140.2,136.6,135.2,132.2,131.1,130 .6,130.3,127.7,126.4,114.6,113.4,61.6,56.3,42.6,5.5ppm; HRMS(ESI):Exact mass calculated for C 25 H 27 NO2Se+H + :454.1280,mass found:454.1280.

[0139] Example 2: Screening of anti-tumor activity of selenium-containing triphenylethylene derivatives.

[0140] 1. Experimental materials:

[0141] (1) Drugs: Tamoxifen, compounds 109-119.

[0142] (2) Cells: human hormone receptor-positive breast cancer cell MCF-7, human triple-negative breast cancer cell SUM-159PT, mouse breast cancer cell 4T1, human endometrial cancer cell AN3CA, and human ovarian cancer cell SK-OV-3.

[0143] (3) Reagents:

[0144] 1) RPMI 1640 culture medium: Gibco, catalog number: 11875093.

[0145] 2) DMEM culture medium: Gibco, catalog number: 11965092.

[0146] 3)MEM culture medium: Biochannel, catalog number: BC-M-020.

[0147] 4) McCoy's 5A medium: Gibco, catalog number: 16600082.

[0148] 3) Fetal bovine serum: Gibco, catalog number: A5669701.

[0149] 4) Thiazolyl blue (MTT): Sigma-Aldrich Company, catalog number: MA0218.

[0150] 5) Dimethyl sulfoxide (DMSO): Beijing Solebow Technology Co., Ltd., catalog number: D8370.

[0151] 2. Experimental Instruments

[0152] (1) Model 3111 CO2 incubator: Thermo Fisher Scientific, USA.

[0153] (2) Type 1389 Biological Safety Cabinet: Thermo Fisher Scientific, USA.

[0154] (3) SpectraMax i3x full wavelength microplate reader: Thermo Fisher Scientific, USA.

[0155] (4) Model 902 Ultra-Low Temperature Refrigerator: Thermo Fisher Scientific, USA.

[0156] (5) High-speed refrigerated centrifuge: Thermo Fisher Scientific, USA.

[0157] (6) Sterilizer: ZEALWAY, USA.

[0158] (7) Ultra-low temperature refrigerator: Thermo Company, USA.

[0159] (8) Microscope: Leica, Germany.

[0160] 3. Experimental Methods

[0161] The MTT method was used to determine the inhibitory effect of compounds 109-119 on breast cancer cell lines MCF-7 and 4T1 cells; the MTT method was used to detect the inhibitory effect of compound 109 on breast cancer cell line SUM-159PT, cancer cell AN3CA cells, and human ovarian cancer cell SK-OV-3. The specific process is as follows:

[0162] (1) MCF-7 cells were prepared into 7×10 4 100 μL of cell suspension (7 × 10 cells / mL) was added to each well of a 96-well plate. 3 cells); 4T1 cells were prepared into 5×10 4 100 μL of cell suspension (5×10 cells / mL) was added to each well of a 96-well plate. 3 AN3CA cells were prepared into 7.5×10 4 100 μL of cell suspension (7.5×10 cells / mL) was added to each well of a 96-well plate. 3 cells); SK-OV-3 cells were prepared into 8×10 4 100 μL of cell suspension (8×10 cells / mL) was added to each well of a 96-well plate. 3cells). They were placed in a CO2 incubator (37°C, 5% CO2) and cultured for 24 h. MCF-7 was cultured in DMEM medium (containing 10% FBS, 1% double antibody), 4T1 and SUM-159PT were cultured in RPMI 1640 medium (containing 10% FBS, 1% double antibody), AN3CA was cultured in MEM medium (containing 10% FBS, 1% double antibody), and SK-OV-3 was cultured in McCoy's 5A medium (containing 10% FBS, 1% double antibody).

[0163] (2) Compounds 109-119 were dissolved in DMSO to prepare 10 mM stock solutions, and the drugs were diluted with complete culture medium to the required different gradient concentrations (1 μM-80 μM). 100 μL of the corresponding drug-containing culture medium was added to each well. A solvent control group (DMSO) and a cell-free culture control group were set up at the same time. The 96-well plate was then placed in a CO2 incubator (37°C, 5% CO2) and cultured for 48 h.

[0164] (3) After 48 hours of culture, discard the drug-containing culture medium, add 200 μL of complete culture medium containing 10% MTT to each well of cells and continue to culture for 4 hours. Carefully aspirate the culture medium, add 100 μL of DMSO to each well and shake thoroughly to dissolve. Use an ELISA reader to measure the absorbance value (OD value) of each well at 490 nm.

[0165] (4) Calculate IC 50 The cell viability was calculated based on the OD value measured above. The calculation formula is as follows: (OD 药物处理组 -OD 无细胞培养组 ) / (OD 溶媒对照组 -OD 无细胞培养组 )×100%, and finally the calculated data were input into GraphPad Prism software to calculate IC 50 .

[0166] 4. Experimental Results

[0167] From the attached Figure 1 , 2 It can be seen that the selenium-containing triphenylethylene derivatives (compounds 109-119) of the present invention showed a certain degree of inhibitory effect on human hormone receptor positive breast cancer cells MCF-7 and mouse triple negative breast cancer cells 4T1. Among them, compound 109 showed an inhibitory effect better than TAM on the above two tumor cells, IC 50 They can reach 8.94μM and 11.31μM respectively.

[0168] Compound 109 was tested for its effect on the viability of human triple-negative breast cancer cell line SUM-159PT, human endometrial cancer cell line AN3CA, and human ovarian cancer cell line SK-OV-3 cells. The results are shown in Table 1.

[0169] Table 1. Effects of TAM and compound 109 on the viability of SUM-159PT, AN3CA and SK-OV-3 cells

[0170]

[0171] Example 3: In vivo study on the anti-breast cancer activity of selenium-containing triphenylethylene derivatives.

[0172] 1. Experimental materials:

[0173] (1) Drugs: Tamoxifen, compound 109.

[0174] (2) Cells: human breast cancer cell line MCF-7, mouse breast cancer cell line 4T1.

[0175] (3) Experimental animals:

[0176] 1) NU / NU nude mice, female, 6 weeks old, purchased from Beijing Weitonglihua Experimental Animal Co., Ltd. (Experimental Animal Production License: SCXK (Beijing) 2021-0011).

[0177] 2) BALB / c mice, female, 6 weeks old, were purchased from Hangzhou Ziyuan Experimental Animal Technology Co., Ltd. (Experimental Animal Production License: SCXK (Zhejiang) 2019-0004).

[0178] (4) Reagents:

[0179] 1) RPMI 1640 culture medium: Gibco, catalog number: 11875093.

[0180] 2) DMEM culture medium: Gibco, catalog number: 11965092.

[0181] 3) Fetal bovine serum: Gibco, catalog number: A5669701.

[0182] 4) CMC-Na: Shanghai Aladdin Biochemical Technology Co., Ltd.

[0183] 5) Sodium chloride injection: Guangxi Yuyuan Pharmaceutical Co., Ltd.

[0184] 6) Dimethyl sulfoxide (DMSO): Beijing Solebow Technology Co., Ltd.

[0185] 2. Experimental Instruments

[0186] (1) Model 3111 CO2 incubator: Thermo Fisher Scientific, USA.

[0187] (2) Type 1389 Biological Safety Cabinet: Thermo Fisher Scientific, USA.

[0188] (3) Model 902 Ultra-Low Temperature Refrigerator: Thermo Fisher Scientific, USA.

[0189] (4) Centrifuge: Thermo Corporation, USA

[0190] (5) Water bath: Changzhou Guoyu Instrument Manufacturing Co., Ltd.

[0191] (6) Sterilizer: Thermo Company, USA.

[0192] (7) Microscope: Leica, Germany.

[0193] (8) Vernier caliper: Sanryo Co., Ltd. of Japan.

[0194] (9) Electronic scale: Weizhixiang small electronic scale.

[0195] 3. Experimental Methods

[0196] (1) Drug preparation: Weigh 70 mg of tamoxifen powder and dissolve it in 2 mL of DMSO to prepare a stock solution with a concentration of 35 mg / mL. Then dilute it in a solvent solution (0.5% CMC-Na) to a concentration of 0.5 mg / mL. The administration volume is 0.2

[0197] 108 mg of compound 109 powder was weighed and dissolved in 2 mL of DMSO to prepare a mother solution with a concentration of 54 mg / mL, and then diluted in a solvent solution (0.5% CMC-Na) to a concentration of 0.331 mg / mL and 0.662 mg / mL, respectively. The dosing volume was 0.2 mL / 20 g, i.e., the dose was 3.31 mg / kg and 6.62

[0198] mg / kg.

[0199] (2) Construction of human breast cancer cell MCF-7 xenograft tumor model:

[0200] Human breast cancer MCF-7 nude mouse transplant tumors were established by inoculating breast cancer MCF-7 cell lines into the subcutaneous tissue of nude mice. MCF-7 cells in the logarithmic growth phase were taken and prepared into 3×10 7 / mL cell suspension, 0.1mL per mouse was inoculated subcutaneously in the right axilla of nude mice, and the cell inoculation volume was 3×10 6 Piece / piece.

[0201] (3) Construction of in situ tumor model of mouse breast cancer cell 4T1:

[0202] Subcutaneous transplantation of mouse breast cancer cell 4T1 was established by inoculating 4T1 cell line into the fourth pair of mammary pads on the right side of BALB / c mice. 4T1 cells in the logarithmic growth phase were taken and prepared into 2×10 6 / mL cell suspension, 0.1mL per mouse was inoculated subcutaneously in the right axilla of nude mice, and the cell inoculation volume was 2×10 5 Piece / piece.

[0203] (4) Experimental groups, medication and evaluation methods:

[0204] Use a vernier caliper to measure the diameter of the transplanted tumor. Wait until the tumor grows to about 70 mm. 3 The animals were randomly divided into a blank control group, a positive drug control group (TAM, 5 mg / kg), a low-dose group of the test sample (compound 109, 3.31 mg / kg) and a high-dose group of the test sample (compound 109, 6.62 mg / kg), wherein the high-dose group was administered at the same concentration as the positive control group. Administration began on the day of grouping, by intragastric administration, with a volume of 0.2 mL / 20 g. The anti-tumor effect of the compound was dynamically observed using the method of measuring tumor diameter. The long diameter a and short diameter b of the tumor were measured with a vernier caliper every three days, and the tumor volume (TV) was calculated as follows: TV = 1 / 2 × a × b 2 .

[0205] Until the tumor volume of the blank group reached an average of 800 mm 3 The experiment was ended at about 1:1. The mice were dissected at the end of the experiment, and the tumors were removed and weighed. The tumor inhibition rate was calculated by the formula: (1-T weight / C weight )×100; where T weight is the average tumor weight of the treatment group, C weight The mean tumor weight of the negative control group.

[0206] Grouping and dosing regimen are shown in Table 2:

[0207] Table 2. Experimental groups and dosing regimens

[0208]

[0209] 4. Experimental Results

[0210] from Figure 3-5 The results show that the compound 109 of the present invention exhibits better tumor growth inhibition activity against MCF-7 xenograft tumors than TAM. The average tumor volume of the TAM-administered group was 283.52 mm 3 The average tumor volumes of the low-dose and high-dose groups of compound 109 were 253.18 mm 3 and 191.74mm 3At the end of the experiment, tumor samples were collected and tumor weight was measured, and the results were basically consistent with the tumor volume measurement results. The average tumor weight of the solvent control group was 0.639g, the average tumor weight of the positive drug control group was 0.33g, and the average tumor weight of the low-dose and high-dose groups of compound 109 were 0.30g and 0.23g, respectively. The tumor inhibition rate was calculated based on the tumor weight of each group of mice, see Table 3.

[0211] Table 3. Tumor inhibition rate of each group of MCF-7 xenograft tumors

[0212]

[0213] Similarly, compound 109 of the present invention also showed better tumor growth inhibition activity than tamoxifen on 4T1 orthotopic transplanted tumors. The average tumor volume of the TAM-administered group was 674.15 mm 3 The average tumor volumes of the low-dose and high-dose groups of compound 109 were 480.73 mm 3 and 408.34mm 3 At the end of the experiment, tumor samples were collected and tumor weights were measured, and the results were basically consistent with the tumor volume measurement results. The average tumor weight of the solvent control group was 1.65g, the average tumor weight of the positive drug control group was 1.24g, and the average tumor weights of the low-dose and high-dose groups of compound 109 were 1.04g and 0.79g, respectively. The tumor inhibition rate was calculated based on the tumor weight of each group of mice, see Table 4.

[0214] Table 4.4 Tumor inhibition rate of each group of T1 transplanted tumors

[0215]

[0216] Figure 6 It means that the weight changes of mice were monitored during the experiment, and each drug administration group had no significant effect on the weight of mice; Figure 7 The results of H&E staining of the organs of mice in each group indicate that each drug-treated group has no damaging effect on the organs of mice.

Claims

1. The compound represented by formula I or its pharmaceutically acceptable salt or isomer Wherein R1 is selected from hydrogen, halogen, hydroxyl, R a OR b O-, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, CN, NO2, formyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C6 alkylthio, substituted or unsubstituted C1-C6 alkylcarbonyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; wherein, The substituted substituents are each independently selected from halogen, C1-C3 alkyl; R2 is selected from R e R f N-, C1~C6 alkoxy, C1~C6 alkyl or halogenated C1~C6 alkyl; wherein R a , R b , R c or R d Each is independently selected from hydrogen, halogen, C1-C3 alkyl or halogenated C1-C3 alkyl; R3 is selected from hydrogen, halogen, hydroxyl, substituted or unsubstituted C1-C6 alkoxy, CN, NO2, formyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C6 alkylthio, substituted or unsubstituted C1-C6 alkylcarbonyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; wherein the substituted substituents are each independently selected from halogen, C1-C3 alkyl; Where R a , R b , R c , R d , R e or R f Each is independently selected from hydrogen, halogen, C1-C3 alkyl or halogenated C1-C3 alkyl.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or an isomer thereof, characterized in that: R1 is selected from hydrogen, halogen, hydroxyl, R a OR b O- or C1~C6 alkoxy; preferably, R1 is selected from hydrogen, chlorine, bromine, iodine, hydroxyl, methoxy or CH3OCH2O-.

3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or an isomer thereof, characterized in that: R2 is selected from R e R f N-or Preferably, R2 is selected from dimethylamino, diethylamino or 4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or an isomer thereof, characterized in that: R3 is selected from hydrogen, C1-C6 alkoxy or C1-C6 alkyl; preferably, R3 is selected from hydrogen, methoxy or isopropyl.

5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or an isomer thereof, characterized in that: The compound shown in formula I has the structure shown in formula I-1 Wherein R1 is selected from hydrogen, chlorine, bromine, iodine, hydroxyl, methoxy or CH3OCH2O-; R2 is selected from dimethylamino, diethylamino or R3 is selected from hydrogen, methoxy or isopropyl.

6. The following compounds or their pharmaceutically acceptable salts or isomers, 7. A method for preparing the compound of formula I according to claim 1, comprising the following steps: wherein R1, R2 and R3 are substituents as defined in formula I, and X is selected from bromine or iodine; Step a): dissolving and mixing the compound of formula V and the compound of formula IV in a solvent, and reacting them in the presence of pinacol and a base to obtain a compound of formula III; Step b): dissolving and mixing the compound of formula III and the compound of formula III-1 in a solvent, and reacting them in the presence of a base and a catalyst to obtain a compound of formula II; Step c): The compound of formula II is reacted with R2H in a solvent in the presence of a base and a catalyst to prepare a compound of formula I.

8. The preparation method according to claim 7, characterized in that: The solvent in step a) is DCE and the base is triethylamine; The solvent in step b) is THF, the base is KOH, and the catalyst is Pd(dppf)2Cl2; The solvent in step c) is DMF, the base is K2CO3, and the catalyst is KI.

9. Use of the compound of formula I according to claim 1 in the preparation of anti-breast cancer, endometrial cancer or ovarian cancer drugs, wherein the breast cancer cells include human hormone receptor-positive breast cancer cell line MCF-7, human triple-negative breast cancer cell line SUM-159PT and triple-negative breast cancer cell line 4T1, endometrial cancer cells include human endometrial cancer cell line AN3CA, and ovarian cancer cells include human ovarian cancer cell line SK-OV-3.

10. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers; the pharmaceutically acceptable carriers refer to various conventional excipients required for preparing different dosage forms, such as diluents, binders, disintegrants, glidants, lubricants, flavoring agents, inclusion materials, adsorption materials, etc., prepared into any commonly used preparations by conventional preparation methods.